Task order title: microbial metabolite mimicry, a nano-drug for colon cancer prevention
Ended Awarded Last action
- Contract number
- 75N91022F00003
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $948,377
Award facts
- Opportunity
-
- TORFPE06 Solicitation number
- Contract value 60% obligated
-
- $948,377.00 Current, with exercised options
- $1,570,991.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $245,908 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $702,469 |
About this award
The National Cancer Institute issued a delivery order to The Institute For Cancer Research on September 15, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and intermediate endpoint biomarker studies supporting a nano-drug for colon cancer prevention, with a ceiling value of $1.57 million and ultimate completion date of June 14, 2026.
PREVENT is a National Cancer Institute IDIQ structured around three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. The Institute For Cancer Research, a non-profit subsidiary of Temple University, operates as the primary PREVENT vehicle holder and delivers preclinical cancer research and drug development services.
Place of performance is Philadelphia, PA. The order carries firm fixed price pricing and no set-aside designation.
SCI-reported labor on this order through FY2025 totaled $609 thousand invoiced across 1,000 contractor hours. FY2023 invoicing was $351 thousand (354 hours at $991.04/hour); FY2024 was $68 thousand (422 hours at $161.22/hour); FY2025 was $190 thousand (224 hours at $849.23/hour). In FY2025, one subcontractor performed 87% of contractor hours, with the Institute maintaining a 0.1 FTE footprint.
Quick answers
Who was awarded contract 75N91022F00003?
75N91022F00003 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022F00003 worth?
The government has obligated $948,377 on 75N91022F00003. Its potential value, with all options, is $1,570,991.
Is contract 75N91022F00003 an order under another contract?
Yes. 75N91022F00003 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00003 competed?
The extent of competition for 75N91022F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award